‘Surprising’ setback: ODAC rebuffs Blenrep for multiple myeloma, citing ocular toxicity
An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used in the proposed dosages for previously treated adult patients with relapsed/refractory multiple myeloma.The FDA Oncologic Drugs Advisory Committee (ODAC) voted 5-3 against belantamab mafodotin (Blenrep, GSK) dosed at 2.5 mg/kg every 3 weeks in combination with bortezomib